The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
Abstract
BACKGROUND: Whether the withdrawal of treatment in patients with nontumoral hyperprolactinemia, microprolactinomas, or macroprolactinomas is safe and effective has been unclear. We performed an observational, prospective study of cabergoline (a dopamine-receptor agonist) withdrawal in such patients. METHODS: The study population included 200 patients--25 patients with nontumoral hyperprolactinemia, 105 with microprolactinomas, and 70 with macroprolactinomas. Withdrawal of cabergoline was considered if prolactin levels were normal, magnetic resonance imaging (MRI) showed no tumor (or tumor reduction of 50 percent or more, with the tumor at a distance of more than 5 mm from the optic chiasm, and no invasion of the cavernous sinuses or other critical areas), and if follow-up after withdrawal could be continued for at least 24 months. RESULTS: Recurrence rates two to five years after the withdrawal of cabergoline were 24 percent in patients with nontumoral hyperprolactinemia, 31 percent in patients with microprolactinomas, and 36 percent in patients; with macroprolactinomas. Renewed tumor growth did not occur in any patient; in 10 female patients (22 percent) and 7 male patients (39 percent) with recurrent hyperprolactinemia, gonadal dysfunction redeveloped. In all diagnostic groups, prolactin levels at the time of recurrence were significantly lower than at diagnosis (P<0.001). The Kaplan-Meier estimated rate of recurrence at five years was higher among patients with macroprolactinomas and those with microprolactinomas who had small remnant tumors visible on MRI at the time of treatment withdrawal than among patients whose MRI scans showed no evidence of tumor at the time of withdrawal (patients with macroprolactinomas, 78 percent vs. 33 percent, P=0.001; patients with microprolactinomas, 42 percent vs. 26 percent, P=0.02). CONCLUSIONS: Cabergoline can be safely withdrawn in patients with normalized prolactin levels and no evidence of tumor. However, because the length of follow-up in our study was insufficient to rule out a delayed increase in the size of the tumor, we suggest that patients be closely monitored, particularly those with macroprolactinomas, in whom renewed growth of the tumor may compromise vision.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I., & Scanlon, M. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311403 · Cited by 699
Dopamine Agonists and Pituitary Tumor Shrinkage
BEVAN, J. S., WEBSTER, J., Burke, C. W., & Scanlon, M. F. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-2-220 · Cited by 469
Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients
Verhelst, J., Abs, R., Maiter, D., van den Bruel, A., Vandeweghe, M., Velkeniers, B., Mockel, J., Lamberigts, G., Petrossians, P., Coremans, P., et al. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5810 · Cited by 449
MOLITCH, M. E., ELTON, R. L., BLACKWELL, R. E., CALDWELL, B., CHANG, R. J., JAFFE, R., JOPLIN, G., ROBBINS, R. J., TYSON, J., & THORNER, M. O. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-60-4-698 · Cited by 435
Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment
Colao, A. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.3.876 · Cited by 276
Self-citationThe Natural History of Untreated Hyperprolactinemia: A Prospective Analysis*
SCHLECHTE, J., DOLAN, K., SHERMAN, B., CHAPLER, F., & LUCIANO, A. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-2-412 · Cited by 271
Colao, A., Sarno, A., Cappabianca, P., Briganti, F., Pivonello, R., Somma, C., Faggiano, A., Biondi, B., & Lombardi, G. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480325 · Cited by 267
Self-citationDi Sarno, A., Landi, M. L., Cappabianca, P., Di Salle, F., Rossi, F. W., Pivonello, R., Di Somma, C., Faggiano, A., Lombardi, G., & Colao, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.8054 · Cited by 247
Self-citationGrowth-hormone and prolactin excess
Colao, A., & Lombardi, G. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03356-x · Cited by 243
Self-citationDrugs Five Years Later: Bromocriptine
VANCE, M. L., EVANS, W. S., & THORNER, M. O. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-1-78 · Cited by 242
Cited by
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline
Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1692 · Cited by 1,844
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Casanueva, F. F., Molitch, M. E., Schlechte, J. A., Abs, R., Bonert, V., Bronstein, M. D., Brue, T., Cappabianca, P., Colao, A., Fahlbusch, R., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02562.x · Cited by 829
Self-citationAdvances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
Self-citationPituitary-Tumor Endocrinopathies
Melmed, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1810772 · Cited by 604
Schlechte, J. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmcp025334 · Cited by 258
Colao, A., Vitale, G., Cappabianca, P., Briganti, F., Ciccarelli, A., De Rosa, M., Zarrilli, S., & Lombardi, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030979 · Cited by 256
Self-citationHyperprolactinemia and Prolactinomas
Mancini, T., Casanueva, F. F., & Giustina, A. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.10.013 · Cited by 256
Mazziotti, G., Mancini, T., Mormando, M., De Menis, E., Bianchi, A., Doga, M., Porcelli, T., Vescovi, P. P., De Marinis, L., & Giustina, A. (2011) · Pituitary · doi:10.1007/s11102-011-0293-4 · Cited by 98
Prolactin in Human Reproduction
Molitch, M. E. (2009) · Yen & Jaffe's Reproductive Endocrinology · doi:10.1016/b978-1-4160-4907-4.00003-6 · Cited by 31
Metadata
- Authors
- Colao, A., Di Sarno, A., Cappabianca, P., Di Somma, C., Pivonello, R., & Lombardi, G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-11-20
- Volume
- 349
- Issue
- 21
- Pages
- 2023-2033
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2034571118
- Cited by
- 336
- References
- 41
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.